Literature DB >> 7070403

Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group.

C B Begg, P P Carbone, P J Elson, M Zelen.   

Abstract

The Eastern Cooperative Oncology Group (ECOG) initiated a program in 1976 to involve community hospitals in multi-institutional clinical trials. The community hospitals can be characterized as generally having no tradition of participating in clinical trials of cancer therapy, whereas the ECOG member institutions are university hospitals or major treatment centers. More than 100 community hospitals participated in 97 randomized trials involving 4506 patients from November 1976 through February 1981. Comparisons between the community hospitals and the ECOG member institutions indicate that the quality of participation was similar, as measured by rates of ineligibility, compliance with the protocol, and submission of data. Objective measures of outcome, such as survival, response, and toxicity, were also comparable. We conclude that under the mechanism adopted by the ECOG, it is possible to include community hospitals in clinical trials of cancer therapy without reducing the quality of the data or compromising the therapeutic outcomes.

Entities:  

Mesh:

Year:  1982        PMID: 7070403     DOI: 10.1056/NEJM198205063061803

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  4 in total

1.  Clinical trial performance of community- vs university-based practices in the submacular surgery trials (SST): SST report no. 2.

Authors:  Neil M Bressler; Barbara S Hawkins; Susan B Bressler; Päivi H Miskala; Marta J Marsh
Journal:  Arch Ophthalmol       Date:  2004-06

2.  Attitude of African-Americans regarding prostate cancer clinical trials.

Authors:  S B Robinson; M Ashley; M A Haynes
Journal:  J Community Health       Date:  1996-04

Review 3.  MRC quality of life studies using a daily diary card--practical lessons learned from cancer trials.

Authors:  P Fayers
Journal:  Qual Life Res       Date:  1995-08       Impact factor: 4.147

4.  Centralised treatment, entry to trials and survival.

Authors:  C A Stiller
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.